Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multiple sclerosis: between wish and reality].

T Kümpfel1, R Hohlfeld

  • 1Institut für Klinische Neuroimmunologie, Klinikum Grosshadern der LMU München.

MMW Fortschritte Der Medizin
|June 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[18F]fluorodeprenyl-D2 PET can detect and monitor astrogliosis in anti-LGI1-IgG autoimmune encephalitis.

European journal of nuclear medicine and molecular imaging·2025
Same author

Rapid differentiation of MOGAD and MS after a single optic neuritis.

Journal of neurology·2024
Same author

Optical coherence tomography assessment of disease activity in cryopyrin-associated periodic syndrome.

European journal of neurology·2024
Same author

Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?

Multiple sclerosis and related disorders·2022
Same author

Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.

Journal of neurology·2022
Same author

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
Same journal

MMW Fortschritte der Medizin·2026
See all related articles

Current multiple sclerosis (MS) treatments involve high-dose glucocorticoids for acute episodes and partially effective immunomodulating therapies. New approaches like natalizumab showed promise but were withdrawn due to side effects, with others in development.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Context:

  • Multiple sclerosis (MS) management relies on established therapies with limited efficacy.
  • Acute MS exacerbations are treated with high-dose intravenous glucocorticoids.
  • Long-term immunomodulatory treatments for MS offer only partial effectiveness.

Purpose:

  • To review current therapeutic guidelines for multiple sclerosis.
  • To discuss the development of novel therapeutic strategies for MS.
  • To highlight emerging treatments targeting specific pathways in MS.

Summary:

  • Current MS therapy guidelines remain unchanged, utilizing high-dose glucocorticoids for acute episodes followed by partially effective immunomodulatory basic therapy.
  • Recent therapeutic advancements include monoclonal antibodies like natalizumab, which demonstrated efficacy but was withdrawn due to severe side effects.

Related Experiment Videos

  • Emerging treatments under investigation include CCR1 antagonists and the interleukin-2 receptor antagonist daclizumab, with a Phase III study planned for the latter.

    • Impact:

    • Identifies limitations in current MS treatment protocols.
    • Highlights the need for more effective and safer therapeutic options for multiple sclerosis.
    • Provides an overview of novel drug candidates and ongoing clinical trials in MS research.